Back to top


(Delayed Data from NSDQ)

$63.18 USD


-1.93 (-2.96%)

Updated Jun 18, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
5Strong Sell3.06%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 47% (134 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

DENTSPLY SIRONA (XRAY) Boosts Clear Aligner Foothold With Buyout

DENTSPLY SIRONA (XRAY) to fortifies its presence further in the clear aligner market with the acquisition of Propel Orthodontics.

All You Need to Know About Dentsply (XRAY) Rating Upgrade to Buy

Dentsply (XRAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Canopy Growth (CGC) to Report Q4 Earnings: What's in Store?

Continued robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal fourth quarter.

Sejuti Banerjea headshot

Large-Cap Stocks Bring Stability to Your Portfolio

Large-caps bring stability to your portfolio because they don't react as aggressively to news and other events.

DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Beat Estimates

DENTSPLY SIRONA (XRAY) witnesses revenue growth in each of its segments in the first quarter.

Dentsply International (XRAY) Surpasses Q1 Earnings and Revenue Estimates

Dentsply (XRAY) delivered earnings and revenue surprises of 30.91% and 10.51%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Henry Schein (HSIC) Hits 52-Week High, Can the Run Continue?

Henry Schein (HSIC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Quidel (QDEL) to Report Q1 Earnings: What's in the Offing?

Quidel (QDEL) is likely to have witnessed recovery in rapid immunoassay revenues during Q1.

Urmimala Biswas headshot

4 Medical Products Stocks Set to Beat This Earnings Season

Rebound in base sales make us optimistic about OMI, INGN, XRAY and CNTG's results this time around.

Cardinal Health (CAH) to Post Q3 Earnings: What's in Store?

Cardinal Health's (CAH) fiscal third-quarter results are likely to reflect solid performance in Pharmaceutical segment.

DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?

DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect weak segmental performance.

BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?

BD's (BDX) second-quarter fiscal 2021 results are likely to reflect strong year-over-year growth in revenues from assays in its Life Sciences segment.

Cerner (CERN) to Report Q1 Earnings: What's in the Offing?

Cerner's (CERN) first-quarter results are likely to reflect gains from strategic deals.

Merit Medical (MMSI) Q1 Earnings and Revenues Beat Estimates

Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q1.

DaVita (DVA) Q1 Earnings Beat Estimates, Revenues Miss Mark

DaVita's (DVA) net dialysis and related lab-patient service revenues rise in Q1.

XRAY vs. ALGN: Which Stock Should Value Investors Buy Now?

XRAY vs. ALGN: Which Stock Is the Better Value Option?

McKesson (MCK) to Report Q4 Earnings: What's in the Offing?

McKesson's (MCK) fiscal fourth-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.

Omnicell (OMCL) Q1 Earnings Beat Estimates, Margins Expand

Omnicell's (OMCL) raises adjusted EPS guidance for 2021 , which buoys optimism.

AmerisourceBergen (ABC) to Post Q2 Earnings: What's in Store?

AmerisourceBergen's (ABC) fiscal second-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.

DexCom (DXCM) Q1 Earnings and Revenues Surpass Estimates

DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth.

Teleflex (TFX) Beats on Q1 Earnings and Revenues, Raises View

The acquisition of Z-Medica and an increase in sales of new products contribute to Teleflex's (TFX) revenue growth in Americas in Q1

Dentsply International (XRAY) Earnings Expected to Grow: Should You Buy?

Dentsply (XRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q4

ABIOMED's (ABMD) international and U.S. Impella revenues improve in Q4.

Surmodics (SRDX) Q2 Earnings Beat Estimates, Revenues Miss

Surmodics (SRDX) records higher revenues in both its core units in the fiscal second quarter.

CONMED (CNMD) Earnings and Revenue Surpass Estimates in Q1

CONMED (CNMD) witnesses growth in revenues in both its segments during Q1.